Publications by authors named "Heather N Moore"
Article Synopsis
- * Effective strategies before and during treatment include identifying high-risk patients, optimizing blood glucose levels, and recommending lifestyle changes such as a low-carb diet and regular exercise.
- * If hyperglycemia occurs, metformin is the first-line treatment, with other medications as alternatives, and a team approach is essential for ongoing monitoring and management to help patients continue their therapy effectively.
Purpose: This study aimed to assess safety and efficacy of a modified KEYNOTE 522 protocol, which incorporated pembrolizumab every 6 weeks, allowing for concomitant dose-dense (14 day) doxorubicin and cyclophosphamide (ddAC). By optimizing this dosing, the intention of this modified protocol was to improve pathologic complete response (pCR) rates in a population associated with a poorer prognosis.
Methods: This was a retrospective, single-center, cohort study.
Article Synopsis
- The purpose of the document is to provide guidance on vaccinating adults with solid tumors or blood cancers, focusing on their specific needs regarding immunization.
- A systematic review was conducted, analyzing studies and trials between 2013 and 2023, resulting in 102 publications, mainly centered on the efficacy of COVID-19 vaccines.
- Key recommendations emphasize the importance of maintaining vaccination status, coordinating among healthcare providers, providing vaccines promptly, and adjusting vaccination plans based on patients' immune status and cancer treatments.
Purpose: SOLAR-1 investigated alpelisib-fulvestrant (ALP + FLV) in patients with HR + /HER2-, PIK3CA-mutated advanced breast cancer and demonstrated a clinically significant increase in all-grade and grade (G) 3-4 hyperglycemia (HG) compared to placebo-fulvestrant. Given high rates of HG, a preventative protocol and identification of associated risk factors was implemented.
Methods: This single-center, retrospective study included patients receiving ALP + FLV.
Persons living with HIV (PLWH) may be at increased risk for polypharmacy (≥5 concomitant medications) over non-PLWH, presumably due to antiretroviral therapy (ARV). Potential concerns associated with polypharmacy include clinically significant drug-drug interactions, adverse drug reactions, increased pill burden, and rising treatment-related costs. Our objective was to evaluate prescription of multiple non-ARV medications to PLWH, compared to non-PLWH, in US outpatient clinics and to identify factors associated with polypharmacy.
View Article and Find Full Text PDFBackground: The comparative impact of chronic viral monoinfection versus coinfection on inpatient outcomes and health care utilization is relatively unknown. This study examined trends, inpatient utilization, and hospital outcomes for patients with HIV, HCV, or HIV/HCV coinfection.
Methods: Data were from the 1996-2010 National Hospital Discharge Surveys.
This review synthesized the literature for barriers to HCV antiviral treatment in persons with HIV/HCV co-infection. Searches of PubMed, Embase, CINAHL, and Web of Science were conducted to identify relevant articles. Articles were excluded based on the following criteria: study conducted outside of the United States, not original research, pediatric study population, experimental study design, non-HIV or non-HCV study population, and article published in a language other than English.
View Article and Find Full Text PDF